this protocol describes a highly reproducible antibody-based method that provides protein level and phosphorylation status information from nanogram quantities of protein cell lysate. nanocapillary isoelectric focusing (cIeF) combines with uV-activated linking chemistry to detect changes in phosphorylation status. as an example application, we describe how to detect changes in response to tyrosine kinase inhibitors (tKIs) in the phosphorylation status of the adaptor protein crkl, a major substrate of the oncogenic tyrosine kinase Bcr-aBl in chronic myeloid leukemia (cMl), using highly enriched cMl stem cells and mature cell populations in vitro. this protocol provides a 2.5 pg/nl limit of protein detection (<0.2% of a stem cell sample containing <10 4 cells). additional assays are described for phosphorylated tyrosine 207 (ptyr207)-crkl and the protein tyrosine phosphatase ptprc/cD45; these assays were developed using this protocol and applied to cMl patient samples. this method is of high throughput, and it can act as a screen for in vitro cancer stem cell response to drugs and novel agents. 
IntroDuctIon
Mapping cancer cell signaling pathways using finite clinical material can support new treatment development and further our understanding of cancer biology. The assessment of signal ing cascades using conventional proteomic technologies often necessitates protein quantities in excess of that which is available, especially when considering human biopsy material or primitive stem cells derived from human or mouse sources.
The development of protein cIEF coupled to antibodybased detection has proven to be both extremely sensitive and frugal in terms of demands on finite samples. The original work by O'Neill et al. 1 used a prototype cIEF system to demonstrate sensitivity down to 25 cells (human prostate cancer cell line LNCaP) for the detection of extracellular signal-related kinases 1 and 2 (ERK1 and ERK2) and their associated phosphorylated states. Different iterations of the technology have subsequently been used in a range of studies, starting with the Firefly instrument (Protein Simple, formerly Cell Biosciences) in which imatinibinduced changes in ERK1 and ERK2 activation status were assessed in human CML cells isolated from total blood, whereas a range of phosphorylation changes in proteins including STAT3 and STAT5 were defined for the K562 CML cell line 2 . Nextgeneration systems (NanoPro 1000, formerly CB1000) have been used to study proteins including AKT, 4EBP1, MET, PTPRC/CD45 and CrkL in a number of leukemias, using different primary cell types including mouse CD138 + cells isolated from bone marrow, human CD34selected acute myeloid leukemia (AML) cells, CMLderived CD34 + cells and dendritic cells (DCs) [3] [4] [5] [6] .
Many malignant diseases are understood to have an under lying stem cell population [7] [8] [9] , which this technology is capable of probing. For myeloproliferative neoplasms and leukemias, this stem cell population has been associated with deregu lated protein tyrosine kinase (PTK) activity (for a review, see Mitelman et al. 10 ), including FMSlike tyrosine kinase 3 (FLT3) in AML 11 , Janus kinase 2 (JAK2) in erythroid neoplasia 12 and BCRABL in CML 13, 14 . TKI therapy using imatinib mesylate (IM) has been shown to inhibit PTK activity in CML [15] [16] [17] [18] . The use of TKIs has improved clinical outcomes markedly for the majority of patients with chronicphase CML who achieve sus tained cytogenetic and molecular response 19, 20 . Nevertheless, second and thirdgeneration TKIs have been developed in response to BCRABL mutations inferring resistance to treatment (for a review, see O'Hare et al. 21 ). Despite continued TKI therapy in CML patients, the minimal effect of TKIs on primitive CML hemopoietic cells results in the persistence of minimal residual disease, which causes disease relapse upon drug withdrawal [22] [23] [24] [25] [26] [27] . Given that CML is a stem cell-driven disease, any new potentially curative therapies must be tested on primary stem cells, which are only available in finite quantities. Thus, methods to screen drug action on suitably limited stem cell populations are of great interest to the scientific community.
Comparison with other methods
Early comparisons of the effect of novel compounds or drugs on very limited numbers of patient stem cells would be of great value to clinicians, both for stratifying treatment response and for devising new therapeutic or curative strategies. Defining these effects in terms of cellular signaling requires the identi fication of proteins and their state of activation in response to posttranslational modifications (PTMs) such as phosphoryla tion. Numerous approaches can be taken to characterize the pro tein state in biological samples, which either use targeted mass spectrometry (MS) or indirect analysis using antibodybased techniques. MS methods such as selected reaction monitoring (SRM) 28 , also known as multiple reaction monitoring (MRM), Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines are highly sensitive and capable of quantitatively detecting atto molar concentrations of protein in complex biological samples (for a review, see Hjelle et al. 29 ). Antibodybased techniques, which can detect down to femtomolar protein concentrations, include western blotting, ELISA, reversephase protein arrays and flow cytometry, as well as the cIEF assay described here.
In CML peripheral blood cells, CrkL, a protein phosphorylated on tyrosine 207 via BCRABL action 30 , is an essential adaptor protein for p210 BCRABL induced leukemogenic transforma tion 31 , and it has been used as a marker for BCRABL status and TKI activity 32, 33 . Direct assay of primitive cells in the CML clone is technically challenging, thus limiting our understanding of the leukemic stem cell response to targeted therapies. The SRM approach can be applied to the measurement of PTM, although this can be very challenging depending on the site of the modi fication and the concentration of the modified isoform of the protein. SRM has been used to monitor the phosphorylation of ERK1 from mouse vascular smooth muscle tissue; however, to measure the PTMs, the starting amount of material was 400 µg and immunoprecipitation was required to enrich the protein before analysis 34 . This requirement would reduce the utility of an SRM assay for highthroughput analysis, whereas the required starting material could be challenging when dealing with scarce primitive stem cells.
Western blot studies have previously been used to detect BCR ABL expression status; however, the instability of the oncogenic tyrosine kinase upon cellular lysis leads to inaccuracies when estimating oncogenic activity 35, 36 . In contrast, detection of acti vated CrkL by western blotting provides an indirect method of determining BCRABL inhibition in response to TKI treatment 32 . However, this approach is of low throughput, with limited scope for multiplexed sample analysis, and, owing to the requirement for bulk CD34 + cells, it is of little use for the analysis of more primitive cells, specifically CD34 + cell subsets in this study.
Flow cytometry can detect activated CrkL in CML CD34 + cells 17 , with singlecell profiling used to explore signaling net works in a number of leukemic cell backgrounds (for a review, see Bendall and Nolan 37 ). Multiplex signaling data can be acquired from as few as 1 × 10 4 cells, meaning that multiple subsets of cells can be identified within a heterogeneous population 38 . Up to 15 distinct signaling events can be assayed simultaneously in live cells. Interference between fluorescent probes is an inherent issue with flow cytometry, which becomes more acute with an increasing number of assayed parameters in any one experiment (for a review, see Bendall et al. 39 ). Nonspecific antibody interac tions within the cell can also be problematic. ELISA represents an alternative to these approaches, and it has been used in previous studies to determine BCRABL activity in Philadelphiapositive cells 40 . ELISA is of high throughput and is capable of processing large sample numbers while using less material than a western blot assay, yet it uses considerably more than flow cytometry.
To enhance the limit of detection (LOD) for markers in stem cells, we used technology that combines cIEF with immunoassay on a new platform (NanoPro 1000; Protein Simple) 1 . This system has been developed on the basis of earlier work, which showed the potential for capillary isoelectric focusing to resolve proteins with high sensitivity while proving to be compatible with immuno assay and chemiluminescence detection (CID; for an overview, see O'Neill et al. 1 ). Therefore, it is theoretically possible for the user to undertake such studies without the NanoPro 1000; however, we have not undertaken an assessment of this option. Key advantages include the ability to handle nanoliter sample volumes with repro ducible, highresolution detection of protein phosphorylation profiles simultaneously for multiple protein targets on extremely small quantities of human tissue. Multiplexed assay times are short, and they allow up to 96 assays to be processed in <18 h. Specifically, we have been able to demonstrate changes in CrkL phosphorylation status using 0.1% of available patient material (<10 4 cells per individual). From this sample, it would be possible to probe for up to 64 different protein targets simultaneously. This approach is not without limitations; novel protein targets would require assay development, which can be timeconsuming, and all potential assays are dependent upon antibody availability. In addition, cIEF immunoassay must be combined with alternative techniques such as flowbased cell sorting to probe different cell lineages (as described in this protocol). Nevertheless, the system is compatible with a wide range of tissue types, including plasma or serum, resected lung tissue, lung and endometrial biopsy mate rial, sputum and cellular organelles. The ability of this platform to handle such a variety of biological samples enables it to be embed ded into laboratory workflows that focus on biomarker validation in blood or biopsy samples, targeted protein PTM assessment in conjunction with MS approaches and signaling cascade mapping in defined primary cell populations.
Experimental design
This protocol defines how cIEF immunoassay can be applied to material from cell lines and the clinic. Specifically, the chronic myelogenous and acute promyelocytic leukemic cell lines K562 and HL60 have been used in Step 1A to develop an assay for the protein CrkL, which is sensitive enough to be applied to clinical material containing ≤5,000 cells (Step 1B). Although this cell line protocol has principally been used for the development of a stem cell-compatible assay here, the method described has been applied to a range of cell lines (i.e., mouse Ba/F3 cells, embryonic stem cells, A549 and HEK 293 human cell lines) and protein targets (for an uptodate list of developed assays, please refer to http://www. scalpl.org/) in our hands. This method is fully transferable, and it can be used to develop assays for any protein using mouse and human cell line material (other cell line sources will probably also be compatible; however, we cannot verify this).
Assay development involves a number of steps, each defining an important aspect of the final protocol for a given protein. It is important to note that the majority of these development steps are determined by the protein of interest; specifically, these relate to a protein's basal isoelectric point (pI), associated isoelectric range (with increasing phosphorylation) and capillary immo bilization chemistry. Acquisition of suitable antibodies for total and phosphorylated entities is essential. Those antibodies that have been shown to work with other immunoassays (i.e., western blot and immunohistochemistry) do not necessarily function well in the cIEF environment; however, we have had consider able success with antibodies developed as part of the Human Protein Atlas (http://www.proteinatlas.org/) program. Assay development should incorporate suitable controls including test for secondary antibody crossreaction with sample minus pri mary antibody (also test for streptavidin-horseradish peroxidase (HRP) crossreaction if using the threestep approach; see Step 2) together with λ phosphatase-treated samples to confirm that protein observations are a result of phosphoryla tion as opposed to other PTMs. It is worth observing that this protocol is nondenaturing, with secondary and tertiary protein structure preserved after isoelectric focusing and immobilization. Consequently, knowledge of a protein's folding structure can be useful when selecting antibodies for assay development, and a focus on antibodies raised to hydrophilic regions is advisable.
It is essential that the LOD for an assay be defined, specifically for those assays designed to probe finite numbers of stem cells. As a guide, a detection limit of ≥20 pg/nl total protein would not be suitable; typically, 2-8 pg/nl total protein is required to probe stem cells, especially when dealing with lowcopynumber pro teins and proteins that undergo transient PTMs. Once developed, if an assay is compatible with lowcellnumber clinical samples, then it is possible to assess the signaling behavior of a given pro tein in human and mouse cells purified using flowbased sort ing ( Step 1B(i)). Issues surrounding high salt content of sample and cell loss during preparation are addressed in this protocol, allowing for the assessment of specific cell linage populations, pertinent in this case for CML therapy but equally applicable to other disease areas. In the majority of cases, the protein concen tration of samples derived from clinical samples (i.e., resected lung tissue) is greatly in excess of the protein requirements for this platform, and the simple protocol used with cell lines can be applied (Step 1A). For samples with protein concentrations of <0.1 mg/ml, the dilution step can be omitted and the approach to sample preparation taken here for stem cells should be used (Step 5). When processing a large number of clinical samples, a number of controls should be applied, including triplicate sam ple loading, positive control (i.e., cell line; n = 1) and a clinical sample pool for intercycle and interexperiment referencing. In addition, during assay development, controls that assess second ary antibody and streptavidinHRP crossreaction with sample and primary antibodies must be used.
The cIEF immunoassay platform uses UVactivated linking chemistry (for details of chemistry used, see O'Neill et al. 1 ), which immobilizes isoelectrically separated proteins to the capillary wall, allowing downstream immunoassay without the need for protein blocking steps. Previous work has shown that the pI of a protein shifts to more alkali values with the inhibition of phos phorylation 1, 41 . Compass software (Protein Simple) is used for every aspect of an assay via three perspectives: 'Assay', 'Run' and 'Analysis'. The assay perspective allows the user to design the assay plate and program the NanoPro 1000 system to process samples in a specific order using defined settings (e.g., antibody incu bation or UV exposure), thus allowing flexibility when design ing complex experiments. Once an assay has been started, the 'Run' perspective gives a realtime display of sample separation on capillary and provides the user with information relating to each stage of the experiment (e.g., sample loading, incubation times and estimated assay completion time). With data acquisi tion complete, the 'Analysis' perspective provides a range of tools to enable the user to analyze results from capillaries. Given the nature of this system, alternative software is not required, with the exception of total area under the curve (AUC) calculations, which require thirdparty software; specifically, we use MedCalc (MedCalc Software).
This technology offers a more sensitive method for assess ing protein phosphorylation status when our workflow is used (Fig. 1) . Specifically, when compared with the prototype systems used in earlier studies 1,2 (Firefly, Protein Simple; formerly Cell Biosciences), the NanoPro 1000 has a number of mechanical enhancements including improved robotic zscheme mapping and liquid handling, a smaller form factor with improved camera and UV attributes. In addition, numerous iterative improvements have been made to consumables chemistry, such as the threestep secondarybiotin to streptavidinHRP detection kit, which can be used in place of conventional secondaryHRP antibody; XDR peroxide for improved chemiluminescence detection with low copynumber proteins; secondgeneration ampholyte premixes, including acidic pH nesting to prevent sample runoff during isoelectric separation; and a host of subtle changes to other con sumable solutions.
Here we use a cIEF immunoassay to study the phosphorylation status of the CrkL adaptor protein in CD34 + CD38 + and primitive CD34 + CD38 − CML cells. The primary tissue is isolated by flow cytometry using leukapheresis samples, followed by culture in growth factors and TKIs, as previously described 42 . A lowionicstrength buffer wash (20 mM bicine and 250 mM sucrose, pH 7.5) is used before lysis with zwitterionic detergent (20 mM bicine, pH 7.6, and 0.6% (wt/vol) CHAPS). Lysates are combined with cIEF rea gents (see Steps 2-18) and loaded onto a multiwell plate. The separation gradients have been optimized for the CrkL assay, taking into account the small number of primary cells used in stem cell studies. After isoelectric separation, proteins are immo bilized using a UVsensitive technique that links the proteins to the capillary wall at their native pI. The CrkL assay was devel oped using control cell lines to determine suitability for clinical sample analysis.
This protocol has been successfully used in two recently pub lished studies involving finite quantities of CML patient mate rial 5, 6 . In one of these studies, Brown et al. 6 focused on the defective function of BCRABLexpressing mature DCs derived from CML patient monocytes and found that dysregulation of ABL1 protein distribution in CMLDCs resulted in changes to CrkL (a substrate protein of ABL1), thereby altering the forma tion of complexes involved in the control of Factin responses. Specifically, CrkL displayed elevated levels of phosphorylation in CMLDCs when compared with normal DCs 6 . Here, we define and compare the proportional degree of phosphorylation for these two cell types, with particular emphasis on the ABL1target residue Tyr207 of CrkL, using both antiCrkL and antipTyr207 CrkL antibodies. Analysis with antibodies that detect total protein produces a profile encompassing PTMs and isoform expression, which can induce changes in the pI of a protein. Antibodies that can detect specific events, such as phosphorylation, are required to further define a protein profile.
In the other study, proteomic analysis of signaling mediated by the chemokine CXCL12 in hematopoietic progenitor cells identified a novel phosphorylation site on the protein tyrosine phosphatase PTPRC/CD45 at residue Ser962. Phosphorylation at this site was shown to be upregulated in the presence of BCR ABL in CD34 + cells derived from patients with CML when com pared with control samples (from patients without CML), using cIEF with both commercially available and inhouse antibodies, respectively 5 . By using the fully optimized PTPRC/CD45 assay developed in our laboratory (for assay development data, see Supplementary Fig. 1 ), we validated the approach using clini cal samples, specifically looking at novel signaling differences between more primitive CD34 + CD38 − CML cells that coenrich with stem cells and more mature CML CD34 + CD38 + progenitor populations, both in TKItreated samples and in untreated con trols. The quantity of clinical starting material needed for this approach is substantially smaller than that required in previous studies using a cIEF platform 1, 2 , and this technique also enables a more detailed analysis of protein phosphorylation than was possible with earlier technologies. Figure 1 | Workflow from patient sample collection to data analysis. Algorithm for the process of sample acquisition, TKI treatment, sorting and lysis (blue section) before application to the cIEF platform (orange section), which is split into sections detailing experimental design, separation, capillary registration and analysis. System experimental design, using the NanaPro 1000, sample, primary antibody, secondary biotin antibody, tertiary streptavidin-HRP antibody and chemiluminescence should be loaded into wells A, B, C, D and J, respectively. Up to eight rows of sample can be loaded (A-H), followed by antibodies and chemiluminescence, by making use of the 384-well plate format. Separation, immobilization and exposure; after the system starts the NanoPro 1000, automatically load the capillaries with sample and initiate isoelectric protein separation over 40 min. At this point, proteins are fixed to the capillary wall during brief UV exposure before washing, antibody probing and chemiluminescence detection. For data analysis, chemiluminescence and fluorescence signatures detected using a CCD camera are converted into electropherogram form. in 30 ml of Purelab ultrapure water, and set the pH with HCl using a pH meter and a magnetic stirrer. Adjust the final volume to 100 ml and store it at RT for up to 6 months. Tris-HCl stacking solution (0.5 M, pH 6.8) Dissolve 6.1 g of Trizma in 30 ml of Purelab ultrapure water, and set the pH with HCl using a pH meter and a magnetic stirrer. Adjust the volume to 100 ml and store it at RT for up to 6 months. SDS stock solution Dissolve 10 g of SDS in 50 ml of Purelab ultrapure water using a magnetic stirrer. Bring the volume to 100 ml and store it at RT for up to 2 months. ! cautIon This solution is toxic if inhaled; dispense the detergent in a fume hood. Ammonium persulfate solution Mix 500 mg of ammonium sulfate in 4.5 ml of Purelab ultrapure water and vortex the mixture to dissolve the contents. Freshly prepare the solution before use. Bromophenol blue stock solution (1%, wt/vol) Dissolve 100 mg of bromophenol blue sodium salt into 2 ml of Purelab ultrapure water and vortex to mix. Adjust the final volume to 10 ml and store it at RT for up to 6 months. Reservoir buffer stock solution (25 mM Tris and 142 mM glycine) Make 10× stock solution by adding 30.33 g of Trizma to 144 g of glycine, and bring the volume up to 500 ml with Purelab ultrapure water until it is dissolved. Adjust the final volume to 1,000 ml. Store the solution at RT for up to 6 months. Reservoir buffer/SDS (wt/vol) 0.05% solution Take 100 ml of reservoir buffer stock solution, add 1 ml of SDS stock solution and bring the volume to 1,000 ml with Purelab ultrapure water. Freshly prepare the buffer before use. Western transfer buffer Dilute 90 ml of reservoir buffer stock solution at a 1:10 ratio with Purelab ultrapure water (add 100 ml of methanol for use with proteins of <40 kDa). Freshly prepare the buffer before use.
MaterIals

REAGENTS
• .59 g in 500 ml of Purelab ultrapure water using a magnetic stirrer. Adjust the final volume to 1,000 ml. Filter sterilize the solution using a 0.2µm sterile filter before use. Store the solution at 4 °C for up to 6 months. Base serum-free medium (SFM) Make the medium in a sterile Duran bottle in a Class II hood. For a 125ml stock, combine 97.25 ml of Iscove'smodified Dulbecco's medium, 25 ml of BIT, 1.25 ml of 200 mM lglutamine, 1.25 ml of 10,000U/ml penstrep, 250 µl of 50 mM 2mercaptoethanol and 500 µl of 10 mg/ml lowdensity lipoprotein while mixing the solution with a magnetic stirrer. Filtersterilize the solution using a 0.2µm sterile filter before storage at 4 °C for up to 1 week. SFM plus growth factors The growth factors are prepared at the following concentrations: SCF, 0.2 ng/ml; GCSF, 1 ng/ml; GMCSF, 0.2 ng/ml; IL6, 1 ng/ml; LIF, 0.05 ng/ml; and MIP1α, 0.2 ng/ml. Once the growth factors are prepared, store them at 4 °C and use them within 2 weeks. IL-6 stock IL6 is supplied as a 25µg lyophilized, carrierfree powder. To regain full activity, IL6 requires reconstitution in 250 µl of 100 mM acetic acid to a concentration of 0.1 mg/ml. Make 20µl aliquots and store them at −20 °C until needed. For a working concentration, freshly prepare the stock. Dilute the stock at a 1:20 ratio with DPBS to a concentration of 0.005 mg/ml. Use 2 µl/10 ml of SFM to give a final concentration of 1 ng/ml.  crItIcal Prepare the reagent under sterile conditions using a Class II microbiological safety cabinet. Do not store it in a frostfree freezer. G-CSF stock GCSF is supplied as a 25µg lyophilized, carrierfree powder. To regain full activity, GCSF requires reconstitution in 250 µl of Purelab ultrapure water to a concentration of 0.1 mg/ml. Make 20µl aliquots and store them at −20 °C until needed. For a working concentration, freshly prepare the stock. Dilute the stock at a 1:50 ratio with DPBS to a concentration of 0.002 mg/ml. Use 5 µl/10 ml of SFM to give a final concentration of 1 ng/ml.  crItIcal Prepare the reagent under sterile conditions using a Class II microbiological safety cabinet. Do not store it in a frostfree freezer. GM-CSF stock GMCSF is supplied as a 10µg lyophilized, carrierfree powder. To regain full activity, GMCSF requires reconstitution in 100 µl of Purelab ultrapure water to a concentration of 0.1 mg/ml. Make 10µl aliquots and store them at −20 °C until needed. For a working concentra tion, freshly prepare the stock. Dilute the stock at a 1:1,000 ratio with DPBS to a concentration of 0.0001 mg/ml. proceDure sample preparation 1| There are two options for preparing samples: the first option (option A) focuses specifically on approaches to preparing cell line material for analysis, and it can be used independently of the second option (option B), which defines a method that is specific for primary stem cell material.
(a) cell lines • tIMInG 1-2 weeks (step 1a(i-xii)), depending on cell recovery time, plus 8 h (step 1a(xiii-xix)) (i) Sample preparation of controls (K562 and HL60 cell lines): thawing and passaging.
Before thawing the cells, prepare the base medium by adding 50 ml of FBS, 5 ml of 200 mM l-glutamine and 2 ml of en-strep to 500 ml of RPMI medium (total volume of 557 ml). Mix by shaking, and place the medium in a water bath that has been prewarmed to 37.5 °C for 30 min. (ii) Dispense 8 ml of RPMI base medium in a 15-ml centrifuge tube using a pipette controller and a 10-ml Stripette. (iii) Thaw the cell ampules in a water bath at 37.5 °C. Transfer the ampules to RPMI base medium prepared in Step 1A(i).
 crItIcal step The cell stock should be partly frozen at this point. As soon as the frozen material is dislodged by melted buffer, transfer the contents to the prewarmed medium. (iv) Wash the ampule by adding 1 ml of RPMI base medium into a tube, quickly pipetting three times (5 s each) and ensuring that the tube walls are fully washed. Remove the medium and add it to the centrifuge tube. This allows for a 1:10 dilution of the frozen cell medium to displace the DMSO. (v) Replace the screw cap and invert the mixture. Centrifuge the mixture at 450g at RT for 3 min to pellet. (vi) Discard the supernatant in liquid Virkon (1%, wt/vol), and resuspend the pellet in 10 ml of RPMI base medium.
Place the mixture in a 25-cm 2 cell culture flask, and incubate it overnight using standard conditions of 37 °C, 5% CO 2 and a humidified atmosphere.
(vii) Assess the cells with a microscope at ×10 magnification to visually determine cell recovery. At this point, there should be some dead cells, but a substantial number of viable cells should be observed (>70% viable).
? trouBlesHootInG (viii) Transfer the cell culture from the flask to a 15-ml centrifuge tube. Take two 50-µl aliquots for cell counting.
 crItIcal step Before decanting the cell culture, gently tap the sides of the flask first to dislodge the cells that have adhered to the bottom of the flask and gently shake the culture. (ix) Pellet the sample by centrifugation at 450g for 3 min at room temperature to remove dead cells and debris. Discard the supernatant in liquid Virkon (1%, wt/vol). Resuspend the cell pellet in 10 ml of prewarmed RPMI base medium and transfer it to a fresh 25-cm 2 cell culture flask. Incubate the suspension overnight under standard conditions. (x) Count the cells. We use an Adam automatic cell counter for large experiments requiring fast cell counting; however, trypan blue exclusion is perfectly adequate. To count using an Adam automatic cell counter, add 50 µl of solution T and 50 µl of solution N (solutions are part of the AccuChip kit) into two separate 0.5-ml Eppendorf tubes. Next, displace the cells that have adhered to the cell culture flask as in Step 1A(viii); take two 50-µl aliquots of cell culture, and add one to each of the Eppendorf tubes containing Adam solutions. Mix gently by pipetting, and place 20 µl from each aliquot into either channel T or channel N (depending on which solution is used) of an Adam AccuChip. Place the chip in the cell counter and start the count. The value given will determine the percentage of the cells that recover during the 24 h after thawing (typically >50%).  crItIcal step Check the cell viability and number weekly using trypan blue to ensure the accuracy of the Adam automatic cell counter. and then seed the cells at a density of 2 × 10 5 cells per milliliter (2 × 10 6 total cell number in 10 ml of prewarmed RPMI base medium, cultured in a 25-cm 2 cell culture flask). Incubate the cells for 1 h using standard conditions (37 °C, 5% CO 2 , 95% relative humidity) before proceeding to treatment (next step). (xiv) Incubate the cells using standard conditions (Step 1A(xiii)), with treatment of interest, for an appropriate time period. We treat with TKIs at the following drug titrations for 5 h using standard conditions (Step 1A(xiii)): (xv) After 4 h of treatment, prepare bicine/CHAPS lysis buffer (50 µl lysis buffer for every 1 ×10 6 cells) and store it on ice until required (up to a maximum of 4 h). (xvi) After the 5-h total drug treatment, repeat Step 1A(viii-x). Resuspend the pellet in 10 ml of DPBS to wash off excess medium. Pellet again and resuspend in 1 ml of DPBS; transfer the mixture to a 1.5-ml microcentrifuge tube and re-pellet using a benchtop microcentrifuge at 1,500g for 3 min at room temperature. Discard the supernatant in liquid Virkon (1%, wt/vol) under a fume hood, and invert the tubes on tissue paper to dry for 20 s. 
cIeF (general procedure)
• tIMInG 3 h, with subsequent overnight assay 2| Design a suitable assay template. We use the 'Assay Perspective' in Compass (Fig. 2) , which allows for selection of sample number and well locations together with primary and secondary antibodies (two-step experiment), or we use primary, secondary and tertiary antibodies (a three-step experiment using biotin-conjugated secondary antibody coupled to streptavidin-conjugated HRP for increased sensitivity). In both two-and three-step experiments, the chemiluminescent reagent location and well number are also defined at this stage. Once an assay plate has been designed, the system must be programmed to allow the automated robotics to collect the samples, antibodies and chemiluminescent reagent in the correct order.
3|
Make up SSD inhibitor mix solution stock as required. Keep it on ice when in use.
4|
Make up G2 premix/ladder stock (PLS; see tables below for volumes defined for up to four cycles). When preparing the stock, always round up to the nearest whole-number volume of the ladder to be used. Make up a minimum volume of 50 ml of PLS stock, as accurate pipetting of <1-µl ladder is difficult to achieve. For samples undergoing >4 cycles, double the volumes involved.  crItIcal step A reverse pipetting technique is essential at this point. The premix solution is extremely viscous and difficult to pipette; to ensure that the correct volume is used, displace the solution three times from the tip before reverse pipetting.  crItIcal step Keep the solution at RT to minimize viscosity. Figure 2 | Assay plate design. The different aspects of assay plate design. (a) 384-well plate layout defines the locations for sample, antibody and chemiluminescence reagent with color-coded rows. The rows can be positioned anywhere on the plate, although row blocks (12 wells) must be placed between columns 1 and 12 or 13 and 24, not centrally (i.e., [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Chemiluminescence reagent must be located two rows from the HRPconjugated antibody. (b) Compass automatically creates a template corresponding to the layout, which allows the user to populate individual wells or whole rows with relevant sample, antibody or reagent information. This is used later for assay analysis. (c) Anticipated results for high and low phosphorylation status (specifically n5-8/L3) for CrkL using K562 and HL60 cell line models, respectively. 5| Dilute a 2 µg/µl sample stock at a 1:5 ratio with SSD, using volumes defined in the table in Step 4. Vortex the stock solution briefly to mix, and keep it on ice.  crItIcal step For finite cell numbers (<5,000 cells), mix the lysate at a 1:1 ratio with SSD to avoid overdilution.
6| Combine the sample from
Step 5 with the appropriate PLS volume and vortex to mix.  crItIcal step Vortex the sample for a minimum of 20 s, ensuring that a vortex forms in the sample solution. A faint pink color should be observed after this.
7|
Load 8 µl per well immediately and keep the plate on ice.
? trouBlesHootInG 8| Dilute the primary antibodies using antibody diluent. Vortex briefly and load 8 µl of antibody per well for samples undergoing ≤4 cycles (double load volume for samples undergoing >4 cycles). ? trouBlesHootInG 9| Dilute secondary biotin antibodies and tertiary streptavidin-conjugated HRP antibodies at a 1:100 ratio with antibody diluent. Vortex briefly and load 8 µl of antibody per well for samples undergoing ≤4 cycles (double load volume for >4 cycles).  crItIcal step The biotin-streptavidin system must be used in conjunction with a three-step assay (see Step 2) . ? trouBlesHootInG 10| Prepare 150 µl of peroxide XDR and Luminol in a 1:1 ratio, and load 8 µl per well for samples undergoing 4 cycles (double the load volume for >4 cycles).  crItIcal step Keep the chemiluminescent reagent at least two rows away from streptavidin-conjugated HRP (normal position is row J; Fig. 2 ).
11|
Once the samples and reagents are loaded onto the plate, replace the lid and centrifuge at 1,000g for 10 min.  crItIcal step After plate centrifugation, visually inspect the wells to ensure that no bubbles are present in the sample wells. Use a spare capillary to rupture them if any bubbles exist. Air bubbles trapped inside a capillary will prevent sample separation (breaks electrical current).
? trouBlesHootInG 12| Replace ultrapure water reservoir and empty waste reservoir (decontaminate as required). Open the Compass and run a cleanup cycle (Instrument → Cleanup → OK). Cleanup takes ~10 min to complete.  crItIcal step Ensure that all capillaries have been removed from the reagents tray before running the cleanup, as the system will move any unused capillaries to waste, which is unnecessary (opened, unused capillaries can be placed in dark, moisture-free storage for later use).
13|
Once the cleanup cycle has been completed, select 'Assay Perspective' in Compass and open the assay file. Check that each cycle is picking up the correct sample and antibody combinations before clicking START. After pressing START, Compass will prompt you to save settings if any unsaved changes have been made to the assay file. It will not be possible to proceed without saving.
14|
Follow onscreen instructions, which should prompt you to replace water and empty waste, and to replace the sponge. ? trouBlesHootInG 15| Replace or top up the wash concentrate, anolyte and catholyte buffers in the reagents tray. Load the capillaries.  crItIcal step Reagent buffers can be topped up over a 48-h period; however, they should be regularly replaced and the containers should be washed in ultrapure water.
? trouBlesHootInG
16|
Place the plate onto a cooled sample tray.  crItIcal step Ensure that the lid is on, as the system will not run without a plate lid.
17| Select the suitable location to save the data after the run has been completed, and click START. The Compass will automatically switch to 'Run Perspective' and provide an estimated time of completion, together with a pictorial breakdown of each cycle and a live camera feed of the separation, including the fluorescence ladder.
18| Upon completion, Compass will create a data file containing the original assay file, run summary information and video, together with the results data. Compass will automatically switch to 'Analysis Perspective' at this point in preparation for data analysis.  pause poInt Results can be analyzed at a time point of your choice.
assay controls-sample phosphatase treatment plus secondary antibody and streptavidin cross-reaction • tIMInG 3 h plus overnight assay  crItIcal The following section describes methods for assay controls to confirm phosphorylate peaks using λ phosphatase together with cross-reaction controls for secondary antibodies and/or tertiary streptavidin-HRP depending upon which approach is taken (two-or three-step approach;
Step 2).
19|
Thaw the λ phosphatase kit on ice.
20|
In a fresh 0.5-ml microtube, dilute 1.25 µl of 1 M DTT with 25 µl of 10× reaction buffer.
21| Transfer 8 µl of lysate (2 mg/ml) into a fresh 0.5-ml microtube and add 1 µl of λ phosphatase together with 1 µl of diluted DTT made in Step 32. Vortex briefly to mix, and pulse-centrifuge the mixture (10 s at 16,100g). Assessing both K562 and HL60 samples treated with TKI provides a detailed analysis of the phosphorylation profile for CrkL, both in the presence and absence of oncogenic tyrosine kinase activity.
22|
Incubate the samples at 37 °C in a water bath for 60 min.
23|
Remove the samples and place them on ice.
24| Process the samples as described in Steps 2-18 using the assay plate design shown in supplementary Figure 1 . 
31|
By using the pI range and immobilization period determined in Step 28, perform primary antibody titration against the default protein concentration (0.1 mg/ml), and probe for 240 min at the following antibody dilutions: 1:10, 1:25, 1:50, 1:100, 1:200 and 1:400 using antibody diluent solution (Fig. 3b) . A nonspecific peak can be detected at pI 6.8 with antibody dilutions <1:50. Optimal peak profile detection (pI 4.5-7) is usually achieved with the 1:100 primary antibody dilution at 240 min, which is a sufficient incubation period for low-signal material. ? trouBlesHootInG 32| Detect chemiluminescence over exposure limits using a 0.4 mg/ml protein concentration (optimized pI, immobilization and antibody settings applied). This concentration of protein will be sufficient to cause overexposure in the majority of cases, and it should not be protein dependent. Quantifiable signal is detectable within 10-240 s of CID within a range of pI 4.5-6.0 for CrkL (this range will be protein dependent), meaning that CID duration can be increased for clinical samples with weaker observed signals. Overexposure can be seen within the range of pI 4.5-5.5 after 240 s of CID (Fig. 3c). 33| Under optimized conditions, determine the protein LOD with an on-capillary protein concentration ranging from 16 to 0.0156 µg.  crItIcal step Different CID periods can be used to either minimize signal burnout or to maximize protein detection.
34|
Calculate the AUC, as in Step 26. For a serial dilution of K562 lysates, as little as 1.6 ng of total protein on capillary can be used to reliably detect CrkL (Fig. 3d) . This value is equivalent to 0.005% of the starting material (1 × 10 6 K562 cells) per capillary (R 2 = 0.9896), with a linear range of detection up to 32 ng of total protein. Intercycle and intracycle reproducibility is high, with a coefficient of variation (CV) of 2.59 and 6.07, respectively.  crItIcal step LOD is assay-specific, and it is dependent on the function of the protein target together with the antibody used. For example, total-AKT has an LOD of 10 ng of total protein, which is insufficient for the analysis of patient samples containing <10 4 cells. A minimum 4.8-ng LOD is required for analysis of these sample types.
? trouBlesHootInG Troubleshooting advice can be found in table 2. 
• tIMInG
Step 1A(i-xii), thawing and passaging of K562 and HL60 cell lines: 1-2 weeks, depending upon the cell recovery time
Step 1A(xiii-xix), TKI treatment, collection and lysis of K562 and HL60 cells: 8 h
Step 1B(i-xii), sample preparation of primary material: 8 h Steps 2-18, cIEF (general procedure): 3 h, with subsequent overnight assay on NanoPro 1000 (~4-15 h)
Step 19-24, sample phosphatase treatment plus secondary antibody and streptavidin cross-reaction: 3 h, plus overnight assay using NanoPro 1000 (~4-15 h)
Step 25-34, cIEF (assay development): 1-8 weeks, depending on the target protein Note that overnight assay using the NanoPro 1000 will take 4-15 h. The precise duration will mainly depend on the number of samples processed and the setting used for antibody incubation, although other settings such as UV exposure will have a small effect on duration. For example, an assay processing four samples in triplicate (12 sample wells in total; assume that the samples reflect necessary controls) probed with primary antibody for 120 min and subsequently processed using a three-step assay ( Step 2) and 10 CID exposures would take ~4 h to complete, after the plate has been set up by the user. Increasing the number of samples and/or the antibody incubation period will increase the time taken for an assay. However, it is worth noting that the NanoPro 1000 runs samples in sets of 12, known as one cycle. The system is capable of running cycles simultaneously, so running 24 samples takes ~5 h rather than 8 h.
antIcIpateD results Therapeutic use of TKIs has been effective for patients with several leukemias [44] [45] [46] [47] [48] . To determine the effect of PTK inhibition on CrkL phosphorylation and to demonstrate the TKI inhibitor assessment potential of the approach, leukemogenic PTK-expressing cell lines were treated with IM and DAS (5 and 0.15 µM, respectively) for 5 h. Treatment with either IM or DAS caused a substantial increase in peaks above pI 5.9, which is characteristic of the HL60 control (Fig. 4a) .
Even with a well-characterized assay such as this, problems can present themselves that cause data analysis difficulties. Examples can include spectra mismatching caused by poor ladder detection by COMPASS (supplementary Fig. 3a) , resulting in spectra that are biologically comparable (as in the case of Fig. 4a ) or identical technical replicates not aligning as they should. This can be easily remedied by manually assigning the ladder values for the mismatched capillaries, instead of relying on Compass-automated detection (supplementary Fig. 3b) . The user can save considerable time and effort by manually checking that automated ladder associations are correct before undertaking detailed analysis of spectral data. Weak, noisy or distorted spectra generated from carefully prepared cell line material can occur in older samples that have undergone freezethaw cycles. cIEF is particularly sensitive to protein instability, especially as phosphorylation events can be unstable during freezing and thawing (M.A.-O., A.P. and A.D.W., unpublished observations). Good laboratory practice can minimize these events, ensuring that multiple aliquots of each new sample are prepared in suitable volumes and stored at −80 °C until required.
λ phosphatase treatment of K562 and HL60 samples ±TKI indicated that peaks detected below pI 5.9 were phosphorylated forms of CrkL (supplementary Fig. 2) . The CrkL protein has been observed with a total of 28 PTMs identified in MS experiments (http://www.phosphosite.org/); however, only pTyr207 has been validated (using a range of methods including western blotting, site-directed mutagenesis and flow cytometry 30, [49] [50] [51] [52] [53] [54] ). Tyr207 phosphorylation has been shown to be the principle phosphorylation event related to BCR-ABL activity 30 . To assess the contribution of pTyr207 in the profile observed for total-CrkL, we probed untreated K562 samples with both anti-CrkL and anti-pTyr207 CrkL antibodies (Fig. 4b) . The resulting profiles overlay perfectly, suggesting that the highly acidic peaks observed in the total-CrkL profile are indeed a result of Tyr207 phosphorylation, in keeping with the use of CrkL protein phosphorylation status as a surrogate marker for BCR-ABL kinase activity 30, 55, 56 . The effect of TKI on the pTyr207 profile demonstrates the superior capacity for DAS to inhibit BCR-ABL and, by direct association, CrkL phosphorylation (Fig. 4b) . λ phosphatase treatment of samples used in Figure 4c shows a marked reduction in acidic peaks, with the anti-Tyr207 antibody failing to detect peaks above pI 6, which are attributed to unphosphorylated CrkL species (Fig. 4c) . The assay development for pCrkL Tyr207, using the protocol defined here, demonstrated LOD of 0.2 ng of total protein (R 2 = 0.9966) with a linear range of detection up to 32 ng of total protein (Fig. 4d) . Reproducibility for the assay is excellent, with intercycle CV = 9.027 and intracycle CV = 9.27. It is worth noting that phospho-specific antibodies can generate spectra with 5-10-fold less intensity than the equivalent total protein, although this is not always the case. Direct comparison of spectra can be difficult when this occurs; however, modification of CID will aid in normalization of spectral intensities. The user must provide an adequate range of camera exposures during assay design to accommodate for these antibody effects. Differences in spectra intensity do not affect percentage peak contribution analysis; however, total AUC will be affected. Treatment with IM or DAS reduced the population of p-CrkL peaks between pI 4.5 and 5.8, with a corresponding increase in peaks above pI 5.9 (Fig. 5a) , when probed with total-CrkL antibody. Potent DAS-mediated changes in the region of pI 5.5 could be seen when compared with IM (Fig. 5a) . These differential DAS-mediated changes were also observed in the limited quantities of clinical CML CD34 + CD38 + committed progenitor cells available for analysis (Fig. 5b) , and again in primitive CML CD34 + CD38 − cells (Fig. 5c) . Given the nature of these samples, the cIEF system is pushed to its operational limits in detecting changes in small numbers of stem cells. Poorly defined, noisy spectra can occur in clinical samples, whereas salt contamination seriously affects protein separation (compare supplementary Videos 1 and 2). The protocol outlined here is designed to minimize the frequency of these events; however, on occasion, clinical samples can be of poor quality, and they can yield little usable data despite the best efforts of those undertaking the research. To determine the value of the approach in quantification of differential drug effects, AUCs for individual peaks were plotted. Analysis of mapped peaks for K562 cells showed a stark contrast between treated and untreated samples (Fig. 5d) . Both TKIs induced marked decreases in pI distribution indicative of phosphorylation changes compared with control; however, DAS had an effect at pI 5.45 (Fig. 5d , blue circle) that can be clearly seen. Furthermore, this DAS-specific effect extends to peaks detected between pI 4.8 and 5.4 (Fig. 5d, blue line) . In primary cells, peak contribution analysis displayed a similar differential effect in both CD34 + CD38 + and CD34 + CD38 − cells treated with IM and DAS (Fig. 5e,f, black triangle, dash) .
Thus, drug effect kinetics and dose response on limited cell populations can be achieved with this protocol in mouse and human cell lines and primary human stem cells. The ability of cIEF immunoassay technology to provide highly resolved, reproducible data on protein phosphorylation events at the nanogram level has previously been demonstrated 1,2 . Here we describe how to use the next-generation cIEF immunoassay platform, which has multichannel capacity, to probe pI protein profiles related to protein phosphorylation. This can be used to investigate LOD from a complex biological sample as a function of observed AUC-type measurements. This provides relative quantification of observed AUC as a function of total protein, which cannot be determined using a statistical definition of LOD based on recombinant protein detection 2 . In the example application we present here, profiles of a key marker for oncogenic PTK activity in response to TKI treatment in CML cells per capillary were achieved, allowing 0.1% of sample containing <10,000 cells to be processed per assay, building on earlier work involving the protein tyrosine phosphatase PTPRC/CD45, in which we used this protocol to assay the levels of 
